MarketCap
BioMarin Pharmaceutical BMRN
$ 67.36
0.99%
Facebook
X
Telegram
BioMarin Pharmaceutical EBITDA per Share | BMRN
Annual EBITDA per Share BioMarin Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.55 | 3.06 | 1.54 | 1.42 | 0.14 | 0.34 | -0.287 | -0.704 | -0.534 | -1.39 | -1.87 | -0.973 | -0.997 | -0.761 | -0.29 | 0.27 | 0.37 | 0.58 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.06 | -1.87 | 0.137 |
Quarterly EBITDA per Share BioMarin Pharmaceutical
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 | 0.76 | - | 0.06 | 1.5 | 1.29 | - | 0.66 | 0.69 | 0.61 | - | 0.21 | 0.4 | 0.48 | - | 0.03 | 0.26 | 0.89 | - | 0.16 | 0.13 | 0.29 | - | 0.12 | 0.06 | 0.73 | - | 0.47 | 0.04 | -0.18 | - | 0.31 | 0.11 | -0.12 | - | 0.26 | - | - | - | 0.1 | -3.23 | -0.38 | - | -0.3 | -0.26 | -0.35 | - | 0.35 | 0.05 | -0.1 | - | -0.09 | 0.03 | -0.17 | - | 0.19 | -0.08 | -0.1 | - | 0.1 | 0.16 | 0.1 | 0.17 | 0.15 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.5 | -3.23 | 0.164 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-6.76 | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-0.71 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
-0.1 | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
-0.82 | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
-1.97 | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-0.25 | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-4.11 | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
1.06 | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
0.12 | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-0.22 | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
-0.2 | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.03 | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-0.04 | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
0.34 | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
0.79 | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-3.51 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-0.04 | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
2.37 | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
-0.03 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.03 | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-0.44 | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-2.5 | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-7.36 | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
0.02 | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
-0.54 | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-2.62 | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-1.81 | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-11.7 | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
-2.06 | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
1.68 | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
-0.4 | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.85 | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.67 | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
0.39 | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
-5.54 | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
-3.37 | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-4.51 | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
-3.47 | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
-3.65 | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-2.68 | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |